Spyre Therapeutics (SYRE) Stock Forecast, Price Target & Predictions
SYRE Stock Forecast
Spyre Therapeutics stock forecast is as follows: an average price target of $50.25 (represents a 86.80% upside from SYRE’s last price of $26.90) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SYRE Price Target
The average price target for Spyre Therapeutics (SYRE) is $50.25 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $71.00 to $40.00. This represents a potential 86.80% upside from SYRE's last price of $26.90.
SYRE Analyst Ratings
According to 5 Wall Street analysts, Spyre Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SYRE stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Spyre Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | Alex Thompson | Stifel Nicolaus | $71.00 | $35.52 | 99.89% | 163.94% |
| Oct 17, 2024 | Colleen Kusy | Robert W. Baird | $50.00 | $32.37 | 54.46% | 85.87% |
| Oct 15, 2024 | Yanan Zhu | Wells Fargo | $40.00 | $30.66 | 30.46% | 48.70% |
| May 10, 2024 | Julian Harrison | BTIG | $40.00 | $35.19 | 13.67% | 48.70% |
The latest Spyre Therapeutics stock forecast, released on Nov 12, 2024 by Alex Thompson from Stifel Nicolaus, set a price target of $71.00, which represents a 99.89% increase from the stock price at the time of the forecast ($35.52), and a 163.94% increase from SYRE last price ($26.90).
Spyre Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 4 |
| Avg Price Target | $71.00 | $53.67 | $50.25 |
| Last Closing Price | $26.90 | $26.90 | $26.90 |
| Upside/Downside | 163.94% | 99.52% | 86.80% |
In the current month, the average price target of Spyre Therapeutics stock is $71.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 163.94% increase as opposed to Spyre Therapeutics's last price of $26.90. This month's average price target is up 32.29% compared to last quarter, and up 41.29% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Oct 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 25, 2024 | BTIG | Buy | Buy | Hold |
| Sep 03, 2024 | Wedbush | - | Outperform | Initialise |
| Jul 16, 2024 | Evercore ISI | - | Outperform | Initialise |
| May 10, 2024 | BTIG | Buy | Buy | Hold |
| Mar 01, 2024 | Wells Fargo | - | Overweight | Upgrade |
Spyre Therapeutics's last stock rating was published by Wells Fargo on Oct 15, 2024. The company gave SYRE a "Overweight" rating, the same as its previous rate.
Spyre Therapeutics Financial Forecast
Spyre Therapeutics Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
Spyre Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SYRE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Spyre Therapeutics EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict SYRE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Spyre Therapeutics's previous annual EBITDA (undefined) of $NaN.
Spyre Therapeutics Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Spyre Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SYRE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Spyre Therapeutics SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Spyre Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SYRE last annual SG&A of $NaN (undefined).
Spyre Therapeutics EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, Spyre Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SYRE previous annual EPS of $NaN (undefined).